We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Karl Swedberg

Karl Swedberg MD, PhD

Senior Professor of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Visiting Professor of Cardiology, National Heart and Lung Institute, Imperial College, London, England, United Kingdom

Karl Swedberg is Senior Professor of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden and Visiting Professor of Cardiology, National Heart and Lung Institute, Imperial College, London. His research interests include beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) and their effects on heart failure (HF) and myocardial infarction (MI), neuroendocrine activation in HF and the treatment of chronic HF. Professor Swedberg was the first to report on the survival benefits of a beta-blocker (1979), ACEI (1987) and angiotensin receptor blocker (2003) in chronic HF. He has published widely, including over 350 original research papers and 25 textbook chapters. Professor Swedberg was included in the 2018 listing of Highly Cited Researchers by Thomson-Reuters. In addition, he has been a steering committee member for numerous outcome trials in HF and MI. He has participated in 32 Data Monitoring Committees (DMC) in clinical trials out of which he has chaired 16 of them.

Professor Swedberg received the 2004 Kaufman Award from Cleveland Clinics (USA) for his HF research, the European Society of Cardiology Gold Medal 2007 for his outstanding contributions to the cardiovascular field and in 2016 the Lifetime Achievement Award from Heart Failure Association (HFA) of ESC. He has been an Honorary Member of the Thai Heart Association since 2007, the Swedish Society of Cardiology since 2008, and the Japan Circulatory Society since 2009. In addition, Professor Swedberg was Editor-in-Chief of European Journal of Heart Failure from 2005 to 2009. He is associate Editor of the European Heart Journal, the leading cardiovascular Journal, since 2012.

Disclosures

Dr. Swedberg receives honoraria from Astrazeneca, Novartis, Pfizer, and Vifor Pharma.